Drug Development
The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink Partners said “fell well below expectations.”
FEATURED STORIES
Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting gene silencers to blood-brain barrier delivery platforms—is entering the pipeline to anchor future combination therapies.
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with Eli Lilly and its Kisunla offering—is focused on a near-term FDA decision for a subcutaneous induction dose of Leqembi, a presymptomatic readout in 2028 and a clutch of next-generation candidates.
BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient access improves.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Aligos Therapeutics, headquartered in South San Francisco, halted the development of ALG-020572, which was being developed in patients with chronic hepatitis B (CHB).
Esai, Biogen, Diadem and ProMis all presented their findings on biomarker research at this year’s International Conference on Alzheimer’s and Parkinson’s Diseases.
Merck’s Keytruda has become an approved treatment for yet another indication: unresectable or metastatic advanced endometrial carcinoma. Know more about it here.
Study after study shows the disease comes with an increased risk of a number of health problems, including diabetes. One of the best ways to avoid those risks is to get vaccinated.
Who is to thank for the COVID vaccine? Many major biopharma companies are asking that question after a series of lawsuits over patent rights to the vaccine and its associated technology.
Today, New Jersey-based Tonix announced that TNX-102 SL failed to generate a statistically significant outcome in fibromyalgia patients.
The platform, called LOCOcyte™, is a cytokine delivery platform that is made of polymer-encapsulated human ARPE-19 cells that produce natural cytokines.
An FDA Investigational New Drug application has been approved for NeuroSense Therapeutics Ltd.’s PrimeC, a potential therapeutic targeting amyotrophic lateral sclerosis (ALS).
ImmunoGen shares inexplicably plunged 23% after the company announced positive Phase III results of its new ovarian cancer treatment.
The 2022 International Conference on Alzheimer’s and Parkinson’s Disease ended last weekend, but it reported on numerous research studies and insights into the diseases.